Trials / Completed
CompletedNCT02192749
Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism
Open, Prospective Trial of Treatment of Autism Spectrum Disorders (ASD) Using Intravenous Infusion of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Translational Biosciences · Industry
- Sex
- All
- Age
- 6 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells administered intravenously (IV) in a series of 4 infusions every 3 months over the course of one year is safe and will induce a therapeutic effect in autism patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Umbilical cord mesenchymal stem cells |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2014-07-17
- Last updated
- 2017-10-13
Locations
1 site across 1 country: Panama
Source: ClinicalTrials.gov record NCT02192749. Inclusion in this directory is not an endorsement.